Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.

92 , 93 , 94 , 95 More recently, however, meta-analysis of 3 controlled trials found only a nonsignificant trend in favor of sulfasalazine over placebo for inducing remission in CD (RR, 1.38; 95% CI, 1.00–1.89; P =0.05), with benefit confined to patients with Crohn's colitis. 96 Slow-release mesalamine was significantly superior to placebo in reducing CDAI score in patients with mild-to-moderate CD in a meta-

also in 5,406 other papers